In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural peptide Oxyntomodulin (human) | Synthetic analog Mazdutide | |
|---|---|---|---|
| Identity | |||
| Kind | Natural peptide | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | No results yet | 186 | |
| Evidence level | No study resultsRegistered trials, no results from human studies | Has results from studies in people | |
| Safety | |||
| Safety results | No safety results | 62 (62 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 2 | 45 · 25 active | |
From the regulatory data of each peptide.
Its most advanced trial is in phase 1. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
No outcome group has study results for two or more of these peptides.
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Mazdutide differs from Oxyntomodulin (human) at 15 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Merck Sharp & Dohme LLC12 participantsJun 2011 to Jul 2011
Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC12 participantsApr 2010 to Jun 2010
Obesity
Top 3 of 45 trials, ranked by phase, then posted results and enrollment: 2 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.912 participantsest. 27 Mar 2026 to est. 31 Dec 2027
Type 2 Diabetes
Huijie Zhang820 participantsest. 1 Sept 2026 to est. 30 Jun 2029
Type 2 Diabetic Kidney Disease
Innovent Biologics (Suzhou) Co. Ltd.731 participants6 Jan 2023 to 9 Apr 2024
Type 2 Diabetes